FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123648178> ?p ?o ?g. }

• W3123648178 endingPage "443" @default.
• W3123648178 startingPage "437" @default.
• W3123648178 abstract "We aimed to investigate the correlation between serum lipoprotein-associated phospholipase A2 (Lp-PLA2) level and acute ischemic stroke (AIS) severity and recurrence, which could indicate the diagnostic and prognostic values of Lp-PLA2. Two hundred and fifty-one AIS patients who were diagnosed in the department of neurology, China-Japan Union Hospital, from April 2018 to June 2019 and 100 non-cerebrovascular disease patients were included in this study. Demographic data and clinical materials including age, sex, BMI, medical history, bad habits, imaging data, blood tests, etc., were collected. Stroke severity and risk were evaluated, respectively. AIS patients were followed up for 6 months for stroke recurrence monitoring. The AIS group had significantly higher Lp-PLA2 level than the control group. High Lp-PLA2 level was the independent risk factor of AIS (OR 1.010; 95% CI 1.007–1.013, P < 0.001). Admission NIHSS was compared between Lp-PLA2 categories dichotomized by median. Serum Lp-PLA2 level was positively correlated with NIHSS (r = 0.268, P < 0.001). Mild stroke group and severe stroke group were defined based on NIHSS. Compared with the mild stroke group, the severe stroke group had higher smoking ratio, posterior circulation stenosis incidence, LDL level, Lp-PLA2 level and admission Essen score. Logistic regression showed Lp-PLA2 levels per 50 ng/mL (OR 1.381, 95% CI 1.212–1.573, P < 0.001) and Lp-PLA2 category (OR 2.420, 95% CI 1.363–4.297, P = 0.003) were both independently associated with severe stroke. During the 6-month follow-up of all 251 AIS patients, 31 stroke recurrence cases were observed. Both Lp-PLA2 levels per 50 ng/mL (OR 1.420, 95% CI 1.212–1.664, P < 0.001) and Lp-PLA2 category (OR 2.726, 95% CI 1.201–6.178, P = 0.016) were significantly associated with the stroke recurrence. Under the receiver Operating Characteristic curve, Lp-PLA2 showed significant predicting ability for stroke recurrence (AUC 0.723; 95% CI 0.620–0.826, P < 0.001). High serum Lp-PLA2 level is correlated with AIS incidence, disease severity and recurrence, which could be utilized to guide clinical practice. Nuestro objetivo fue investigar la correlación entre el nivel sérico de fosfolipasa A2 asociada a lipoproteína (Lp-PLA2) y la gravedad y recurrencia de los accidentes cerebrovasculares agudos (ACV), lo cual podría ser indicativo de los valores diagnóstico y pronóstico de Lp-PLA2. Se incluyó en el estudio a 251 pacientes de ACV diagnosticados en el Departamento de Neurología del Hospital China-Japan Union, desde abril de 2018 a junio de 2019, y a 100 pacientes sin enfermedad cerebrovascular. Se recopilaron los datos demográficos y materiales clínicos incluyendo edad, sexo IMC, historia médica, malos hábitos, estudios por imagen, análisis de sangre, etc. Se evaluaron la gravedad del accidente cerebrovascular y el riesgo, respectivamente, realizándose un seguimiento de supervisión de la recurrencia del accidente, de 6 meses de duración, a los pacientes de ACV. El grupo ACV tuvo un nivel de Lp-PLA2 significativamente superior al del grupo control. El nivel alto de Lp-PLA2 fue el factor de riesgo independiente de ACV (OR: 1,010; IC 95%: 1,007-1,013; p < 0,001). Se comparó el valor de la escala NIHSS durante el ingreso entre las categorías Lp-PLA2, dicotomizadas por mediana. El nivel sérico de Lp-PLA2 se correlacionó positivamente con NIHSS (r = 0,268; p < 0,001). Se definieron el grupo de accidente leve y el grupo de accidente grave sobre la base de NIHSS. En comparación con el grupo de accidente leve, el grupo de accidente grave tenía un ratio más alto de fumadores, incidencia de estenosis circulatoria posterior, nivel de LDL, nivel de Lp-PLA2 y puntuación Essen durante el ingreso. La regresión logística reflejó que los niveles Lp-PLA2 por 50 ng/ml (OR: 1,381; IC 95%: 1,212-1,573; p < 0,001) y la categoría Lp-PLA2 (OR: 2,420; IC 95%: 1,363-4,297; p = 0,003) estaban independientemente asociados a los accidentes graves. Durante el seguimiento de 6 meses realizado a los 251 pacientes de ACV, se observaron 31 casos de recurrencia de accidentes. Tanto los niveles de Lp-PLA2 por 50 ng/ml (OR: 1,420; IC 95%: 1,212-1,664; p < 0,001) como la categoría Lp-PLA2 (OR: 2,726; IC 95%: 1,201-6,178; p = 0,016) estuvieron significativamente asociados a la recurrencia de accidentes. En la curva ROC, Lp-PLA2 reflejó una capacidad de predicción significativa para la recurrencia de accidentes (AUC: 0,723; IC 95%: 0,620-0,826; p < 0,001). El alto nivel sérico de Lp-PLA2 está correlacionado con la incidencia de ACV, gravedad de la enfermedad y recurrencia, lo cual podría ser utilizado como guía para la práctica clínica." @default.
• W3123648178 created "2021-02-01" @default.
• W3123648178 creator A5006583743 @default.
• W3123648178 creator A5025594135 @default.
• W3123648178 creator A5089079624 @default.
• W3123648178 date "2021-05-01" @default.
• W3123648178 modified "2023-09-29" @default.
• W3123648178 title "The diagnostic and prognostic performance of Lp-PLA2 in acute ischemic stroke" @default.
• W3123648178 cites W1997102345 @default.
• W3123648178 cites W2006421710 @default.
• W3123648178 cites W2020220432 @default.
• W3123648178 cites W2052016798 @default.
• W3123648178 cites W2069931757 @default.
• W3123648178 cites W2099306543 @default.
• W3123648178 cites W2105934060 @default.
• W3123648178 cites W2114408062 @default.
• W3123648178 cites W2118801006 @default.
• W3123648178 cites W2158958417 @default.
• W3123648178 cites W2163291110 @default.
• W3123648178 cites W2163526866 @default.
• W3123648178 cites W2527652416 @default.
• W3123648178 cites W2532781823 @default.
• W3123648178 cites W2619839728 @default.
• W3123648178 cites W2800703974 @default.
• W3123648178 cites W2810701711 @default.
• W3123648178 cites W2898213480 @default.
• W3123648178 cites W2899719560 @default.
• W3123648178 cites W2903696936 @default.
• W3123648178 cites W2984635218 @default.
• W3123648178 cites W3000689456 @default.
• W3123648178 cites W4231037567 @default.
• W3123648178 cites W4255683973 @default.
• W3123648178 doi "https://doi.org/10.1016/j.medcli.2020.11.034" @default.
• W3123648178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33483146" @default.
• W3123648178 hasPublicationYear "2021" @default.
• W3123648178 type Work @default.
• W3123648178 sameAs 3123648178 @default.
• W3123648178 citedByCount "5" @default.
• W3123648178 countsByYear W31236481782022 @default.
• W3123648178 crossrefType "journal-article" @default.
• W3123648178 hasAuthorship W3123648178A5006583743 @default.
• W3123648178 hasAuthorship W3123648178A5025594135 @default.
• W3123648178 hasAuthorship W3123648178A5089079624 @default.
• W3123648178 hasConcept C118552586 @default.
• W3123648178 hasConcept C120665830 @default.
• W3123648178 hasConcept C121332964 @default.
• W3123648178 hasConcept C126322002 @default.
• W3123648178 hasConcept C127413603 @default.
• W3123648178 hasConcept C151956035 @default.
• W3123648178 hasConcept C16568411 @default.
• W3123648178 hasConcept C2777034527 @default.
• W3123648178 hasConcept C2778163477 @default.
• W3123648178 hasConcept C2780072125 @default.
• W3123648178 hasConcept C2780645631 @default.
• W3123648178 hasConcept C61511704 @default.
• W3123648178 hasConcept C71924100 @default.
• W3123648178 hasConcept C78519656 @default.
• W3123648178 hasConceptScore W3123648178C118552586 @default.
• W3123648178 hasConceptScore W3123648178C120665830 @default.
• W3123648178 hasConceptScore W3123648178C121332964 @default.
• W3123648178 hasConceptScore W3123648178C126322002 @default.
• W3123648178 hasConceptScore W3123648178C127413603 @default.
• W3123648178 hasConceptScore W3123648178C151956035 @default.
• W3123648178 hasConceptScore W3123648178C16568411 @default.
• W3123648178 hasConceptScore W3123648178C2777034527 @default.
• W3123648178 hasConceptScore W3123648178C2778163477 @default.
• W3123648178 hasConceptScore W3123648178C2780072125 @default.
• W3123648178 hasConceptScore W3123648178C2780645631 @default.
• W3123648178 hasConceptScore W3123648178C61511704 @default.
• W3123648178 hasConceptScore W3123648178C71924100 @default.
• W3123648178 hasConceptScore W3123648178C78519656 @default.
• W3123648178 hasIssue "9" @default.
• W3123648178 hasLocation W31236481781 @default.
• W3123648178 hasOpenAccess W3123648178 @default.
• W3123648178 hasPrimaryLocation W31236481781 @default.
• W3123648178 hasRelatedWork W1580426574 @default.
• W3123648178 hasRelatedWork W1970383787 @default.
• W3123648178 hasRelatedWork W1986078235 @default.
• W3123648178 hasRelatedWork W2043123170 @default.
• W3123648178 hasRelatedWork W2089620537 @default.
• W3123648178 hasRelatedWork W2275480158 @default.
• W3123648178 hasRelatedWork W3095306390 @default.
• W3123648178 hasRelatedWork W3209251735 @default.
• W3123648178 hasRelatedWork W4238089809 @default.
• W3123648178 hasRelatedWork W4241346791 @default.
• W3123648178 hasVolume "156" @default.
• W3123648178 isParatext "false" @default.
• W3123648178 isRetracted "false" @default.
• W3123648178 magId "3123648178" @default.
• W3123648178 workType "article" @default.